{"query":"Ensysce Biosciences Lynn Kirkpatrick opioid overdose protection news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://ir.ensysce.com/news/press-releases/detail/208/ensysce-biosciences-expands-global-opioid-patent-portfolio","title":"Ensysce Biosciences Expands Global Opioid Patent Portfolio","content":"Lynn Kirkpatrick, CEO of Ensysce Biosciences. \"This patent strengthens our pain portfolio program and underscores the transformative","score":0.8055255,"raw_content":null},{"url":"https://ir.ensysce.com/news/press-releases/detail/196/ensysce-biosciences-advances-breakthrough-opioid-with","title":"Ensysce Biosciences Advances Breakthrough Opioid With Built-In ...","content":"Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback ... Lynn Kirkpatrick","score":0.8003337,"raw_content":null},{"url":"https://ir.ensysce.com/news/press-releases/detail/209/ensysce-biosciences-provides-enrollment-update-on-pivotal","title":"Press Releases - Ensysce Biosciences, Inc. (ENSC)","content":"## Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain. (NASDAQ:ENSC) (\"Ensysce\" or the \"Company\"), a clinical-stage pharmaceutical company pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced it has enrolled **50%** of subjects targeted for interim review in its pivotal Phase 3 clinical trial of PF614, the Company's next-generation opioid candidate engineered to deliver powerful pain relief with built-in abuse protection.. PF614 leverages Ensysce's proprietary chemical activation technology, which is designed to keep the opioid inactive until swallowed, limiting the impact of tampering and dose manipulation while enabling extended-release pain control. By engineering opioids with intrinsic safeguards against tampering, misuse, and overdose, Ensysce aims to offer safer, life-saving options for patients in need of powerful pain relief. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected.","score":0.7707586,"raw_content":null},{"url":"https://www.stocktitan.net/news/ENSC/ensysce-biosciences-ceo-dr-lynn-kirkpatrick-and-creighton-university-a1v7e1pbuo7q.html","title":"Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and ... - Stock Titan","content":"Ensysce's modified oxycodone remains inactive unless taken orally and prevents overdose while maintaining pain relief efficacy, earning FDA Fast Track","score":0.75312227,"raw_content":null},{"url":"https://ir.ensysce.com/news/press-releases/detail/206/ensysce-biosciences-issues-annual-shareholder-letter","title":"Ensysce Biosciences Issues Annual Shareholder Letter","content":"PF614-MPAR is engineered to \"switch off\" opioid release in an overdose scenario, offering a potentially life-saving advance for patients who","score":0.7253574,"raw_content":null}],"response_time":1.32,"request_id":"4504e427-8db7-4370-b07e-10d262bbf7c8"}